News

May 03, 2017

The HLH Region of Interest assay is designed to assess genes that may cause autosomal recessive or X-linked recessive forms of primary HLH. Developed in collaboration with experts in the Division of Immunology at Boston Children’s Hospital, this Region of Interest evaluates 20 genes related to the known causes of HLH within a rapid turnaround time. More information can be found here....

January 30, 2017

Claritas is pleased to announce the addition of the mitochondrial DNA analysis to their Flagship Claritas Clinical Exome. When ordered, the mitochondrial genome and exome are sequenced simultaneously by deep NGS sequencing. More information is available here....

January 05, 2017

On January 4, 2017, Claritas Genomics received the New York State Clinical Laboratory Permit with specific approval for the Claritas Clinical Exome and the Pediatric Neurology Region of Interest. Read the Press Release here. ...

January 05, 2017

Dr. Stephanie Hallam joined Claritas Genomics on November 29, 2016, as Vice President of Molecular Diagnostics. Read the full press release here....

January 03, 2017

A Washington Post article, published on December 30, 2016, describes the Weekes family's journey with Boston Children's Hospital to find a molecular diagnosis for their son Quinlan, who has experienced seizures and other serious medical issues since birth. The article describes Claritas Genomics' founder Dr. Tim Yu's use of the WuXi NextCODE platform to interpret Quinlan's DNA sequence which resulted in a diagnosis that explained Quinlan's...

October 27, 2016

Claritas Genomics employees presented three posters at ASHG 2016 in Vancouver, Canada. John Thompson, PhD and Chief Technology Officer, presented on "Improved sensitivity for clinically relevant variants using orthogonal sequencing." Eric White, PhD and Director of Assay and Technology Development, presented on "Improving coverage of poorly sequenced regions in clinical exomes." Natalie Vena, GC and Genetic...

October 12, 2016

Claritas Genomics’ Elizabeth Mullady, MLS(ASCP), MHA, Director of Quality Assurance and Regulatory Affairs speaks on October 18, 2016 at the 10th annual Lab Quality Confab in New Orleans. Ms. Mullady and co-presenter Randall Querry of the American Association for Laboratory Accreditation discuss “Lessons Learned at Claritas from Simultaneous Accreditation to CLIA and ISO 15189: Combining the World’s Most Accepted QMS with CLIA.” Read more about their talk by visiting...

October 04, 2016

Join John Thompson, PhD, Chief Technology Officer at Claritas Genomics; Natalie Vena, Genetic Counselor at Claritas Genomics; and David Miller, MD, PhD, Medical Director at Claritas Genomics and Clinical Geneticist at Boston Children's Hospital as they discuss the technology of whole exome testing, the algorithms used by clinicians when considering whether to order genetic testing, and case studies showing the utility of whole exome sequencing.

This webinar, recording June 28, 2016 is available...

September 22, 2016

Advances in Genome Biology and Technology (AGBT) 2016 is holding a Precision Medicine conference in Scottsdale, Arizona, September 22-24. As per the AGBT website, "This new meeting will bring together leading genomics researchers, healthcare professionals, and healthcare industry stakeholders to rigorously explore exciting developments at the interface of genomics, medicine, and health." Claritas's Chief Technology Officer, Dr. John Thompson, is attending and will present a poster entitled, "Improved sensitivity for...

August 22, 2016

Claritas Genomics has launched the Bone Marrow Failure Region of Interest test, an exome-based test that assesses 86 genes related to known causes of hereditary bone marrow failure. Developed in collaboration with experts in hematology at Boston Children's Hospital, this assay's first results are issued at 4 weeks, providing critical information to providers and patients for treatment and management decisions. ...

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.